FDA Investigator Roseline N Boateng
Roseline N Boateng has conducted inspections on 6 sites in 1 countries as of 15 Dec 2023. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
6
Last Inspection Date:
15 Dec 2023
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America
FDA Investigators that have inspected at least one site in common with Roseline N Boateng:
Anthony W Hite,
Azeezat M Lawal,
Brandy N Lepage,
Brooke K Higgins,
Bruce C Kovak,
Clarice J Ahn,
Craig D Zagata,
Deborah J Parris,
Demitria J Xiradakis,
Diane T Bargo,
Donald G Gordon,
Dr. Robert C Horan, MD,
Emest F Bizjak,
Eric L Dong, BS,
Gale L Glinecki,
Jai P Singh,
James W Leonette,
Jesse P Hardin,
Joey C West,
John Dan,
Johnny D Nwankwo,
Joseph L Despins, PhD,
Juliana M Badalucco,
Karen A Briggs,
Kathryn A Nagy,
Keith M Reilly,
LCDR Chad N Thompson,
Lori S Lawless,
Marcellinus D Dordunoo,
Marcia D Fields,
Marcus A Ray,
Margaret E Sarles,
Mary F Finn,
Mary M Finn,
Melissa J Garcia,
Merideth K Rose,
Michael A Taylor,
Michael L Casner,
Mindy M Chou,
Natasha Gupta,
Nebil A Oumer,
Nina D Patel,
Paul E Stein,
Rachel C Harrington,
Samina S Khan,
Sena G Dissmeyer,
Shusheen A Alexander,
Sony Mathews,
Steven J Libal,
Steven J Thurber,
Suzanne M Healy,
Tajah L Blackburn,
Tammy S Notto,
Tekalign Wondimu,
William J Leonard,
Yaharn Su,
Zakaria I Ganiyu,
Zhao Wang, PhD,
Zhong Li, PhD
Roseline N Boateng's Documents
Publish Date | Document Type | Title |
---|---|---|
January, 2022 | EIR | Granules Pharmaceuticals Inc. - EIR, 2022-03-02 |
March, 2022 | FDA 483 | Arnold Professional Pharmacy - Form 483, 2022-03-18 |
January, 2022 | FDA 483 | Granules Pharmaceuticals Inc. - Form 483, 2022-01-28 |
December, 2021 | EIR | Aphena Pharma Solutions - Maryland, LLC - EIR, 2021-12-15 |
December, 2021 | FDA 483 | Aphena Pharma Solutions - Maryland, LLC - Form 483, 2021-12-15 |
February, 2020 | FDA 483 | Jubilant Cadista Pharmaceuticals, Inc. - Form 483, 2020-02-28 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more